Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 2773-2776, September 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burke, R. E.
Right arrow Articles by McGuire, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burke, R. E.
Right arrow Articles by McGuire, W. L.

Lactate Dehydrogenase in Estrogen-responsive Human Breast Cancer Cells1

Robert E. Burke, Steven C. Harris and William L. McGuire2

Department of Medicine [R. E. B., W. L. M.] and Pathology [S. C. H.], The University of Texas Health Science Center, San Antonio, Texas 78284

Lactate dehydrogenase activity (LDH) was measured in the MCF-7 human breast cancer cell line derived at the Michigan Cancer Foundation from a patient with metastatic breast adenocarcinoma. LDH was found in the 46,000 x g supernatant of cell lysates, but not in the culture medium. Only the fifth isozyme (LDH-5) could be demonstrated by cellulose acetate electrophoresis and relative heat inactivation studies.

When endogenous steroids were removed from the medium, addition of estrogen to the growth medium for several days elevated LDH 2-fold above controls; LDH was not altered when MCF-7 cells were treated with progesterone, hydrocortisone, prolactin, insulin, or triiodothyronine. A physiological concentration (0.1 nM) of 17ß-estradiol was sufficient to produce a maximal LDH increase. There were no qualitative isozyme changes in response to estrogen.

LDH activity may therefore be a useful marker protein for studying hormone action in the MCF-7 human breast cancer cell line.

1 Supported in part by grants from the National Cancer Institute (CA 11378, CB 23862, and CA 09042), the American Cancer Society (BC-23G), and the Medical Research Service of the Audie L. Murphy Veterans Administration Hospital, San Antonio, Texas.

2 To whom requests for reprints should be addressed.

Received 3/ 9/78. Accepted 5/30/78.




This article has been cited by other articles:


Home page
Clin. Chem.Home page
M. Maekawa, T. Taniguchi, J. Ishikawa, H. Sugimura, K. Sugano, and T. Kanno
Promoter Hypermethylation in Cancer Silences LDHB, Eliminating Lactate Dehydrogenase Isoenzymes 1-4
Clin. Chem., September 1, 2003; 49(9): 1518 - 1520.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.